Fibroza pulmonară idiopatică cu reacţii adverse severe la corticoterapie- prezentare de caz

Abstract

Idiopathic pulmonary fibrosis (IPF) remains the most common of the idiopathic interstitial pneumonias and portends a poor prognosis. The number of deaths related to IPF is nearly 14 times greater than those from asbestosis. The disease course in IPF is variable, with many patients remaining stable for long periods of time while a significant proportion experience exacerbations leading to respiratory failure and death. Traditional IPF pharmacotherapy has emphasized immunosuppression, but corticotherapy can have severe side effects.